Detail akcie PROCEPT BioRobot Rg online

Business Summary: PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Procept Biorobotics Corp revenues increased 48% to $231.7M. Net loss decreased 9% to $65.7M. Revenues reflect United States segment increase of 45% to $203.8M, Outside United States segment increase of 72% to $27.9M. Lower net loss reflects Commercial-stage Surgical Robotics segment loss decrease of 5% to $72.8M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.41 to -$1.19.